Why the study?
How can 18F-FDG-PET/CT and novel imaging modalities be utilized to evaluate atherosclerosis and inflammation?
How can 18F-FDG-PET/CT and novel imaging modalities be utilized to evaluate atherosclerosis and inflammation?
18F-FDG-PET/CT and emerging modalities like PET/MRI offer valuable non-invasive methods for evaluating atherosclerosis and vascular inflammation.
Answers are grounded in this paper and cite their sources.
May aid non-invasive atherosclerosis assessment; leaves open need for prospective outcome trials.
Atherosclerosis is a prevalent cardiovascular disease marked by inflammation and the formation of plaque within arterial walls. As the disease progresses, there is an increased risk of major cardiovascular events. Owing to the nature of atherosclerosis, it is imperative to develop methods to further understand the physiological implications and progression of the disease. The combination of positron emission tomography (PET)/computed tomography (CT) has proven to be promising for the evaluation of atherosclerotic plaques and inflammation within the vessel walls. The utilization of the radiopharmaceutical tracer, 18F-fluorodeoxyglucose ((18)F-FDG), with PET/CT is invaluable in understanding the pathophysiological state involved in atherosclerosis. In this review, we will discuss the use of (18)F-FDG-PET/CT imaging for the evaluation of atherosclerosis and inflammation both in preclinical and clinical studies. The potential of more specific novel tracers will be discussed. Finally, we will touch on the potential benefits of using the newly introduced combined PET/magnetic resonance imaging (MRI) for non-invasive imaging of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Alie et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: